1例多药联用致室性心律失常的药学监护

doi:10.19803/j.1672-8629.20230216

中国药物警戒 ›› 2023, Vol. 20 ›› Issue (11): 1279-1281.
DOI: 10.19803/j.1672-8629.20230216

1例多药联用致室性心律失常的药学监护

郑金凤, 王景红^*

中国中医科学院望京医院药学部,北京 100102

收稿日期:2023-04-10 出版日期:2023-11-15 发布日期:2023-11-13
通讯作者: ^*王景红,女,本科,主任药师,医院药学。E-mail：wangjinghong2002@126.com
作者简介:郑金凤,女,硕士,主管药师,临床药学。
基金资助:
中国中医科学院望京医院自主选题（WJYY-ZZXT-2023-18）;北京市中医管理局北京市第三批中药骨干人才培养项目（京中医科字[2021]161号）。

Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination

ZHENG Jinfeng, WANG Jinghong^*

Wangjing Hospital of China Academy of Chinese Medical Sciences, Beijing 100102,China

Received:2023-04-10 Online:2023-11-15 Published:2023-11-13

摘要/Abstract

摘要： 目的通过1例心衰合并肺部感染应用多种药物致尖端扭转型室速患者的病例介绍,探讨临床药师开展危重症患者药学服务及严重不良反应防范的切入点。方法临床药师参与1例多药联用致恶性心律失常治疗过程,协助医生识别可疑药物,处理药源性尖端扭转型室性心动过速（TdP）并对主要药物治疗实施药学监护。结果临床药师协助医师调整用药方案,对严重不良反应采取有效措施,取得良好效果。结论临床药师参与治疗团队,以药品不良反应为切入点,对重症患者开展药学监护,可有效保障患者用药安全。

关键词: 间断扭转型室速, QT间期延长, 药学监护, 药品不良反应, 多药联用

Abstract: Objective To explore the entry point of clinical pharmacists to carry out pharmaceutical care for critically ill patients and prevent serious adverse reactions through the introduction of a case of a patient with heart failure complicated with pulmonary infection induced by multi-drug tip torsion ventricular tachycardia. Methods Clinical pharmacists participated in the treatment of a case of malignant arrhythmia caused by multi-drug combination, assisted doctors in identifying suspicious drugs, dealing with drug-induced TdP and implementing pharmaceutical care. Results Clinical pharmacists assisted physicians to adjust the medication regimen and take effective measures for serious adverse reactions, which achieved good results. Conclusion Clinical pharmacists can effectively ensure the safety of medication by participating in the treatment team, taking pharmacy as the breakthrough point and acting as the assistant of doctors.

Key words: torsade de pointes(TdP), prolonged QT interval, pharmaceutical care, adverse drug reaction, multidrug combination

中图分类号:

R994.11

郑金凤, 王景红. 1例多药联用致室性心律失常的药学监护[J]. 中国药物警戒, 2023, 20(11): 1279-1281.

ZHENG Jinfeng, WANG Jinghong. Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination[J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1279-1281.

参考文献

[1] CAO KJ, CHEN KP, CHEN ML, et al.Chinese expert consensus on ventricular arrhythmias[J]. Chinese Journal of Cardiac Pacing and Electrophysiology(中国心脏起搏与心电生理杂志), 2020, 34(3):189-253.
[2] Chinese Society of Cardiology. Expert consensus on emergency management of cardiac arrhythmias[J]. Chinese Journal of Cardiology(中华心血管病杂志), 2013, 41(5): 363-376.
[3] DREW BJ, ACKERMAN MJ, FUNK M, et al.Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation[J]. J Am Coll Cardiol, 2010, 55(9): 934-947.
[4] WOOSLEY RL,HEISE CW, GALLOT ET, et al. QTdrugs list [EB/OL]. (2014-08-01)[2023-02-23]. http://www.crediblemeds.org.
[5] NARANJO CA, BUSTO U, SELLERS EM, et al.A method for estimatingthe probability of adverse drug reactions[J]. Clin Pharmacol Ther,1981,30(2): 239-245.
[6] JIANG WP.Guidelines for the use of amiodarone in antiarrhythmic therapy (2008)[J]. Chinese Journal of Cardiac Pacing and Electrophysiology(中国心脏起搏与心电生理杂志), 2008,22(5):377-385.
[7] TISDALE JE, CHUNG MK, CAMPBELL KB,et al.Drug-induced arrhythmias: a scientific statement from the american heart association[J]. Circulation, 2020, 142(15): 214-233.
[8] LI L,WEN J, FANG DM, et al.A systematic retrospective analysis of quinolones -induced extension of QT interval[J]. Tianjin Pharmacology(天津药学), 2019, 31(2): 15-21.
[9] WANG L, ZHANG L, ZHU L, et al.Research progress of osimertinib-related cardiotoxicity[J]. Chinese Journal of Hospital Pharmacy(中国医院药学杂志),2023, 43(13): 1516-1520.
[10] DE MARINIS F,WU YL,DE CASTRO G JR,et al. ASTRIS: a global real-world study of osimertinib in >3000 patients with EGFR T790M positivenon-small-cell lung cancer[J]. Future Oncol, 2019, 15(26): 3003-3014.
[11] PATEL SR, BROWN SN, KUBUSEK JE, et al.Osimertinib-induced cardiomyopathy[J].JACC Case Rep, 2020, 2(4): 641-645.
[12] TISDALE JE, JAYNES HA, KINGERY JR, et al.Development andvalidation of a risk score to predict QT interval prolongation inhospitalized patients[J]. Circ Cardiovasc Qual Outcomes, 2013, 6(4): 479-487.

[1]	贾晋生, 刘红亮, 王青, 侯永芳, 李馨龄. 基于知识图谱联合ERNIE-DPCNN模型的药品不良反应自动关联性评价方法研究[J]. 中国药物警戒, 2024, 21(2): 163-166.
[2]	李应芬, 韩雷. 319例注射用脑蛋白水解物药品不良反应报告分析[J]. 中国药物警戒, 2024, 21(2): 195-198.
[3]	徐伟佳, 彭崎, 黄海渝, 张磊姣, 肖华, 吴雪. 285例新型抗肿瘤药物不良反应分析[J]. 中国药物警戒, 2024, 21(2): 199-203.
[4]	郭清华, 彭笑笑, 朱萍, 刘西霖, 杨颖华, 陈志海. 氨氯地平过量致多器官功能障碍综合征1例分析[J]. 中国药物警戒, 2024, 21(2): 204-207.
[5]	方美琳, 郑慧敏, 王存泽, 王凌, 阮君山. 注射用奥沙利铂致全身肌肉疼痛1例分析[J]. 中国药物警戒, 2024, 21(2): 208-210.
[6]	陈玉艳, 张明霞, 张涛, 张晋. 斯鲁利单抗注射液致间质性肺炎不良反应1例分析[J]. 中国药物警戒, 2024, 21(2): 213-215.
[7]	曹桂萍, 邓琳琳, 朱干红, 陆颖, 马爽, 陈玲玲, 刘丽丽. 天麻首乌片致严重肝损伤1例分析[J]. 中国药物警戒, 2024, 21(2): 216-218.
[8]	高云娟, 赵旭, 白天凯, 柏兆方, 王伽伯, 宋海波, 肖小河. 基于不良反应监测大数据的药品安全风险发现与识别策略[J]. 中国药物警戒, 2024, 21(1): 1-5.
[9]	郭龙鑫, 高云娟, 吴承钊, 龙敏娟, 祝胜凯, 宋海波, 赵旭, 肖小河. 基于不良反应监测大数据的中药药源性肝损伤风险信号新发现及易感因素初探[J]. 中国药物警戒, 2024, 21(1): 15-19.
[10]	蒋文硕, 杨莉. 694例癫痫医师药师联合门诊患者药品不良反应分析[J]. 中国药物警戒, 2024, 21(1): 102-106.
[11]	陈华炎, 江东波, 郭春连, 杨家琪, 黎雨欣, 蔡伟明. 326例奈玛特韦片/利托那韦片治疗新型冠状病毒感染安全性分析[J]. 中国药物警戒, 2024, 21(1): 107-110.
[12]	刘赛月, 吕小琴, 周耘. 疑似药品不良反应死亡病例调查及报告实施要点[J]. 中国药物警戒, 2023, 20(9): 971-974.
[13]	里筱竹, 王蔷, 逄瑜, 张轶菁. 个例药品不良反应报告管理浅析与思考[J]. 中国药物警戒, 2023, 20(9): 975-977.
[14]	逄瑜, 刘博, 吕少俐, 王涛, 邢颖, 秦星宇, 田月洁, 吴文宇. 基于国际药物警戒经验探讨收集患者报告的意义[J]. 中国药物警戒, 2023, 20(9): 978-981.
[15]	刘文东, 崔欢欢, 王晓晗, 苏娴, 王海学. 我国儿童用药临床试验期间药物警戒监管体系现状及思考[J]. 中国药物警戒, 2023, 20(9): 1002-1006.

1例多药联用致室性心律失常的药学监护

Pharmaceutical care of one case of malignant arrhythmia induced by multidrug combination

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics